168 related articles for article (PubMed ID: 24088751)
1. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia.
Oshima Y; Yuji K; Tanimoto T; Hinomura Y; Tojo A
Intern Med; 2013; 52(19):2193-201. PubMed ID: 24088751
[TBL] [Abstract][Full Text] [Related]
2. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
3. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
4. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Al-Samkari H; Van Cott EM; Kuter DJ
Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
[TBL] [Abstract][Full Text] [Related]
7. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
[TBL] [Abstract][Full Text] [Related]
8. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
Kowalczyk M; Rubinstein PG; Aboulafia DM
J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Depré F; Aboud N; Mayer B; Salama A
Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
[TBL] [Abstract][Full Text] [Related]
10. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
Cines DB; Gernsheimer T; Wasser J; Godeau B; Provan D; Lyons R; Altomare I; Wang X; Lopez A
Int J Hematol; 2015 Sep; 102(3):259-70. PubMed ID: 26201709
[TBL] [Abstract][Full Text] [Related]
12. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
13. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
15. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
Shinohara K; Kambara N
Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
Prica A; Sholzberg M; Buckstein R
Br J Haematol; 2014 Dec; 167(5):626-38. PubMed ID: 25155450
[TBL] [Abstract][Full Text] [Related]
18. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis.
Tjepkema M; Amini S; Schipperus M
Crit Rev Oncol Hematol; 2022 Mar; 171():103581. PubMed ID: 35007700
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
20. Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database.
Fang Q; Huang F; Liang J; Chen Y; Li C; Zhang M; Wu X; Luo W
Expert Opin Drug Saf; 2023; 22(8):707-714. PubMed ID: 36803342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]